COLY-MYCIN M

LOE Approaching

colistimethate

NDAINJECTIONINJECTABLE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

CLINICAL PHARMACOLOGY Typical serum and urine levels following a single 150 mg dose of Coly-Mycin M Parenteral IM or IV in normal adult subjects are shown in Figure 1. Higher serum levels were obtained at 10 minutes following IV administration. Serum concentration declined with a half-life of 2–3…

Clinical Trials (4)

NCT06198764Phase 3Recruiting

A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection

Started Jul 2023
NCT02452047Phase 3Completed

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Started Aug 2015
50 enrolled
Bacterial Infections
NCT01940731Phase 2Unknown

Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults

Started Oct 2013
NCT01844778Phase 4Completed

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Started Aug 2013
60 enrolled
Cystic Fibrosis